© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to February
>50x family-selective HPK1 kinase inhibitor
tumor clearance w/ PD-1i (oral 100 mpk BID)
from IRAK4 inhibitor and homology modeling
ACS. Med. Chem. Lett., Feb. 19, 2021
Bristol Myers Squibb, Cambridge, MA
6. The Bristol Myers Squibb (BMS) HPK1 kinase inhibitor, “compound 24” is an oral tool compound intended for cancer immunotherapy, with >50x selectivity against family members including GLK. The…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.